Partner Emeritus at Domain Associates

Where does Jesse Treu work?

Jesse Treu is General Partner at Domain Associates.

What check size does Jesse Treu write?

Jesse Treu typically writes checks of $100K – $5M.

What boards does Jesse Treu sit on?

Jesse Treu holds tracked board seats at Afferent Pharmaceuticals, Aldeyra Therapeutics, CoLucid Pharmaceuticals, Sebacia.

What companies has Jesse Treu invested in?

Investments tracked here include Afferent Pharmaceuticals, BiPar Sciences, CoLucid Pharmaceuticals, Nps Pharmaceuticals, Regado Biosciences, Somaxon Pharmaceuticals, Tandem Diabetes Care, Inc., Veracyte, Xagenic.

Where did Jesse Treu go to school?

Jesse Treu studied at Princeton University (M.A., Ph.D.); Rensselaer Polytechnic Institute (B.S., Physics).

Jesse Treu

Investor

General Partner at Domain Associates

New York City

Writes $100K – $5M checks · typically $1.5M

Find your path to Jesse

223 people in our graph can introduce you to Jesse.

Each arrow is one introduction. Sign up to fill in the first one.

Ask Stephen Tulipano to introduce you to Jesse

You →Stephen · together at Aldeyra Therapeutics →Jesse

Ask Jamie Chen to introduce you to Jesse

You →Jamie · together at Aldeyra Therapeutics →Jesse

Ask Sam Okafor to introduce you to Jesse

You →Sam · 2 people · together at Sebacia →Jesse

Your email: the people you already email who know Jesse
2nd- and 3rd-degree connections: people you know who worked, studied or invested with Jesse
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Experience

Stellar Energy Foundation, Inc.Chairman and CEOcurrent2016 — present
Domain Associates, LLCFounding Partnercurrent1985 — presentPrinceton, NJ

Deals · 4

SebaciaBoard seat

via Domain Associates · filed Sep 2019 · $15M raise

Afferent PharmaceuticalsBoard seat

via Domain Associates · filed Jul 2015 · $55M raise

Aldeyra TherapeuticsBoard seat

via Domain Associates · filed Jan 2015 · $18.4M raise

CoLucid PharmaceuticalsBoard seat

via Domain Associates · filed Jan 2015 · $37.1M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Investor

BiPar SciencesNps PharmaceuticalsRegado BiosciencesSomaxon PharmaceuticalsTandem Diabetes Care, Inc.VeracyteXagenic

Sources: SEC Form D filings · curated public sources.

Leave your own feedback

Colleagues at Domain Associates

Brian Dovey

Partner at Domain Associates

Brian Halak

Managing Partner at Medical Excellence Capital

Debra K. Liebert

Investor at Domain Associates

Dennis Podlesak

Venture Partner at Domain Associates

Eckard Weber

Venture Partner at Domain Associates

James Blair

Partner at Domain Associates

Kathleen Schoemaker

Partner and CFO at Domain Associates

Kim Kamdar

Managing Partner at Medical Excellence Capital

Frequently asked questions

Who is Jesse Treu?: Partner Emeritus at Domain Associates
Where does Jesse Treu work?: Jesse Treu is General Partner at Domain Associates.
What check size does Jesse Treu write?: Jesse Treu typically writes checks of $100K – $5M.
What boards does Jesse Treu sit on?: Jesse Treu holds tracked board seats at Afferent Pharmaceuticals, Aldeyra Therapeutics, CoLucid Pharmaceuticals, Sebacia.
What companies has Jesse Treu invested in?: Investments tracked here include Afferent Pharmaceuticals, BiPar Sciences, CoLucid Pharmaceuticals, Nps Pharmaceuticals, Regado Biosciences, Somaxon Pharmaceuticals, Tandem Diabetes Care, Inc., Veracyte, Xagenic.
Where did Jesse Treu go to school?: Jesse Treu studied at Princeton University (M.A., Ph.D.); Rensselaer Polytechnic Institute (B.S., Physics).